TABLE 3.

miRNAs levels of UC patients in different studies.

miRNA name	Sample type	Disease	Control	Sample size	Expression states	Sensitivity (%)	Specificity (%)	References
miR-223	Feces	aIBD	iIBD	aIBD/iIBD: 30/15	↑	80	93	Schönauen et al. (2018)
	Feces	aUC	HC	aUC/HC: 10/15	↑	90	87	Schönauen et al. (2018)
	Serum	aUC	iUC	aUC/iUC: 24/22	↑	79	72	Polytarchou et al. (2015b)
miR-21	Plasma	aUC	IBS/HC	aUC/IBS/HC: 37/30/30	↑	88	92	Ahmed Hassan et al. (2020)
miR-92a	Plasma	aUC	IBS/HC	aUC/IBS/HC: 37/30/30	↑	88	100	Ahmed Hassan et al. (2020)
miR-4454	Serum	aUC	iUC	aUC/iUC: 24/22	↑	70	68	Polytarchou et al. (2015b)
Panel of (miR-598/miR-642)	Plasma	UC	CD	UC/CD: 21/12	↑/↑	72	86	Netz et al. (2017)
miR-23a-3p	Serum	aUC	iUC	aUC/iUC: 24/22	↑	79	68	Polytarchou et al. (2015b)
miR-320e	Serum	aUC	iUC	aUC/iUC: 24/22	↑	67	67	Polytarchou et al. (2015b)
miR-16-2-3p	Serum	GR	GS	GR/GS: 37/39	↓	74	97	Luo et al. (2018)
miR-30e-3p	Serum	GR	GS	GR/GS: 37/39	↓	85	89	Luo et al. (2018)
miR-32–5p	Serum	GR	GS	GR/GS: 37/39	↓	97	60	Luo et al. (2018)
miR-642a-5p	Serum	GR	GS	GR/GS: 37/39	↓	92	73	Luo et al. (2018)
miR-150–5p	Serum	GR	GS	GR/GS: 37/39	↓	67	97	Luo et al. (2018)
miR-224–5p	Serum	GR	GS	GR/GS: 37/39	↓	90	97	Luo et al. (2018)

↓ indicates inhibition/reduction of miRNA expression in the condition described in the corresponding "disease" and "sample type" item, while ↑ indicates increase/promotion; UC, ulcerative colitis; aIBD, active inflammatory bowel diseases; iIBD, inactive inflammatory bowel diseases; aUC, active ulcerative colitis; HC, healthy control; iUC, inactive ulcerative colitis; IBS, irritable bowel syndrome; CD, Crohn's disease; GR, glucocorticoid-resistant; GS, glucocorticoid-sensitive.